טוען...
Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC
SIMPLE SUMMARY: Non-small cell lung cancer (NSCLC) claims almost 80% of the total lung cancer cases, with the late-stage disease having an estimated median survival time of up to five years. Patients with NSCLC benefit from traditional maximum tolerated dose (MTD) chemotherapy alone or combined with...
שמור ב:
| הוצא לאור ב: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8071233/ https://ncbi.nlm.nih.gov/pubmed/33920884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13081901 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|